Skip to content

Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02494557
Acronym
CAD-risk
Enrollment
108
Registered
2015-07-10
Start date
2014-09-30
Completion date
2015-03-31
Last updated
2017-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arteriosclerosis

Brief summary

Diabetic type 2 patients (DB2) has a higher prevalence of coronary artery disease (CAD) than non-diabetic persons. Presence of CAD results in murmurs arising from the filling of the arteries and can be detected by the CADScor System and can together with biological patient profile indicate the risk of presence of CAD in the patient. In the pilot study 100 asymptomatic DB2-patients examined with CADScor System and biomarkers will be compared with computed tomography (CT) cardiography and single-photon emission computed tomography (SPECT) for assessing if combination of patient profile (gender, age etc) combined with above measures may give rise to new improved risk scoring method for he DB2-patient.

Detailed description

The study is intended as a pilot observational study for evaluation of a new risk scoring method, CADScor System, is relevant for assessment of CAD in the DB2-patient. The primary end point will be to document that the hypothesis of combining the CADScor System measure with other patient profile data will increase the accuracy of the method for determination of risk of presence of CAD. The secondary endpoint will be to show that a receiver operating characteristic curve (ROC) of \> 80% for correct determination of presence of CAD will be achieved. The further objective of the study will be to confirm the relevance of performing a large scale study with equivalent objectives. As controls in the study will be applied CT angiography, CT-calcium and resting and drug induced CT-scintigraphy. It is assumed that 15-20 of enrolled patients in the study will suffer from CAD.

Interventions

None listed

Sponsors

Steno Diabetes Center Copenhagen
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Acarix
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients suffering from diabetes type 2 * Both sexes * Patients between 40 and 80 years * Patients without chest pain at rest and labor * Patients having a normal electrocardiogram (ECG, i.e. without Q-peaks/ T-peak abnormalities in sinus rhythm) * Patients having intact skin over sternum

Exclusion criteria

* Patients suffering from a heart disease * Patients already having received heart surgery * Patients with pacemaker or other implanted electronic device * Patients suffering from allergy against iodine and iodine containing substances * Patients with estimated GFR below 50 ml/min/1.73 sqm m * Patients suffering from adenosine intolerance or known allergic asthma * Patients not being capable of understanding the patient information of the study * Patients who are pregnant * Patients suffering from allergy to adhesives

Design outcomes

Primary

MeasureTime frameDescription
Acoustic Cad-score1 yearComparison of an non-invasive acoustic Cad-score as risk prediction for presence of coronary artery disease with control studies of CT-angiography and resting and drug induced CT scintigraphy

Secondary

MeasureTime frameDescription
The degree of presence of coronary artery disease (CAD) in Diabetic type 2 patients (DB2) patients1 yearResting and drug induced perfusion test will be compared to CT Angiography for determining the degree of presence of CAD when including patient parameters characterizing the status and severity of the DB2.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026